Standard doses of naloxone are often insufficient to restore normal breathing during opioid-induced respiratory depression (OIRD) after overdoses involving fentanyl and sufentanil.
Standard doses of naloxone are often insufficient to restore normal breathing during opioid-induced respiratory depression (OIRD) after overdoses involving fentanyl and sufentanil.
Read More
A Purdue Pharma study explored nalmefene and naloxone for the reversal of respiratory depression induced by fentanyl in a clinical opioid-induced respiratory depression model.
Read More
Implanted under the skin, the Naloximeter senses dropping oxygen and sends a warning notification to a mobile app. If the user doesn’t engage with the warning message within 30 seconds, the device releases stored naloxone.
Read More
Surprisingly, naloxone was associated with improved clinical outcomes in both drug-related cardiac arrests and non-drug-related cardiac arrests.
Read More
The implantable device, tested in animal models, continuously monitors vital signs and automatically administers naloxone during opioid overdose.
Read More
Adding a newly identified compound makes naloxone more potent and longer lasting, a mouse study shows.
Read More
A data-driven intervention engaging communities to deploy evidence-based practices did not significantly reduce opioid-related overdose deaths.
Read More
The nasal spray, available at pharmacies without a prescription, is designed to counteract opioid overdoses.
Read More
A head-to-head pharmacodynamic study examined the ability of both intranasal nalmefene (Opvee) and intranasal naloxone to reverse opioid-induced respiratory depression.
Read More
In some of the most notable pharmaceutical approvals from 2023, drugs for RSV, CF, COVID-19, sickle cell disease, and opioid overdose received an FDA stamp in 2023.
Read More
The US Food and Drug Administration approved a 3-milligram naloxone hydrochloride nasal spray for over-the-counter, nonprescription use for the emergency treatment of known or suspected opioid overdose.
Read MoreThe FDA approved Narcan 4 mg naloxone hydrochloride nasal spray for over-the-counter, nonprescription use. The approval is the first for a naloxone product without a prescription.
Read MoreThe FDA approved Amphastar Pharma’s naloxone hydrochloride nasal spray (4mg) for the emergency treatment of known or suspected opioid overdose.
Read More
Harm reduction is an evidence-based, often life-saving approach that directly engages people who use drugs to prevent overdose, disease transmission and other harms.
Read More
Teva says its generic version of the nasal spray Narcan is the first to arrive on the market.
Read More
Kaléo will pay the United States $12.7 million to resolve allegations that Kaléo caused the submission of false claims for the drug Evzio, an injectable form of naloxone hydrochloride for opioid overdose.
Read More
A new NIH study found that non-Hispanic Black individuals in four US states experienced a 38% increase in the rate of opioid overdose deaths from 2018 to 2019, while the rates for other race and ethnicity groups held steady or decreased.
Read More
The FDA approved an 8mg dose naloxone hydrochloride nasal spray to treat opioid overdose, an increase from the previous 2 mg and 4 mg approved products.
Read More
Kaleo Inc has discontinued its naloxone hydrochloride injection product Evzio and its authorized generic, according to industry reports.
Read MoreAccess to naloxone remains limited but the FDA continues to support efforts to expand access in order to get the drug to those at risk of opioid overdose.
Read More
A new study from researchers at the University of Illinois at Chicago finds that only one-third of pharmacies in Philadelphia carry naloxone nasal spray, a medication used to rapidly counter the effects of opioid overdose.
Read More
Kaleo will offer an Evzio generic (naloxone HCl injection) at a list price of $178 per carton (two auto-injectors per carton).
Read More
Kaleo, the company that makes a naloxone auto-injector called Evzio, is coming under fire for raising the price of a two-pack from $690 to $4500 since 2014.
Read More
The FDA wants the proposed app to connect opioid users experiencing an overdose with nearby carriers of the prescription drug naloxone (the antidote for an opioid overdose).
Read More
